{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT03740204",
            "orgStudyIdInfo": {
                "id": "1R01MH116205",
                "type": "NIH",
                "link": "https://reporter.nih.gov/quickSearch/1R01MH116205"
            },
            "organization": {
                "fullName": "Massachusetts General Hospital",
                "class": "OTHER"
            },
            "briefTitle": "The Role of Estrogen in the Neurobiology of Eating Disorders",
            "officialTitle": "The Role of Estrogen in the Neurobiology of Eating Disorders: A Study of Cognitive Flexibility and Reward in Eating Disorders",
            "therapeuticArea": [
                "Other"
            ],
            "study": "the-role-of-estrogen-in-the-neurobiology-of-eating-disorders"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-05",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2019-06-13",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2025-09-30",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2025-12-31",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2018-11-05",
            "studyFirstSubmitQcDate": "2018-11-09",
            "studyFirstPostDateStruct": {
                "date": "2018-11-14",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-05-30",
            "lastUpdatePostDateStruct": {
                "date": "2024-05-31",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "PRINCIPAL_INVESTIGATOR",
                "investigatorFullName": "Madhusmita Misra",
                "investigatorTitle": "Division Chief, Pediatric Endocrinology",
                "investigatorAffiliation": "Massachusetts General Hospital"
            },
            "leadSponsor": {
                "name": "Massachusetts General Hospital",
                "class": "OTHER"
            }
        },
        "oversightModule": {
            "oversightHasDmc": true,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "This is a randomized, double blind, placebo-controlled study of the effects of transdermal estradiol versus placebo on cognitive flexibility, reward processing, and eating disorder pathology in hypoestrogenemic female adolescents and young adults (ages 14-35 years) with an eating disorder characterized by extreme dietary restriction and/or excessive exercise. Subjects will be randomized 1:1 to 12 weeks of transdermal estradiol with cyclic progesterone or placebo patches and cyclic placebo pills. Study visits include a screening visit to determine eligibility and visits at baseline, 8 weeks, and 12 weeks. Study procedures comprise behavioral, neuroimaging, and endocrine assessments."
        },
        "conditionsModule": {
            "conditions": [
                "Eating Disorders",
                "Hypoestrogenemia"
            ],
            "keywords": [
                "Adolescent",
                "Amenorrhea",
                "Anorexia Nervosa",
                "Cognitive Flexibility",
                "Dietary Restriction",
                "Eating Disorders",
                "Estrogen",
                "Excessive Exercise",
                "Females",
                "Hypoestrogenemia",
                "Reward"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE2"
            ],
            "designInfo": {
                "allocation": "RANDOMIZED",
                "interventionModel": "PARALLEL",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "QUADRUPLE",
                    "whoMasked": [
                        "PARTICIPANT",
                        "CARE_PROVIDER",
                        "INVESTIGATOR",
                        "OUTCOMES_ASSESSOR"
                    ]
                }
            },
            "enrollmentInfo": {
                "count": 120,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "17-\u03b2 estradiol with cyclic progesterone",
                    "type": "EXPERIMENTAL",
                    "interventionNames": [
                        "Drug: 17-\u03b2 estradiol transdermal patches with cyclic progesterone"
                    ]
                },
                {
                    "label": "Placebo",
                    "type": "PLACEBO_COMPARATOR",
                    "interventionNames": [
                        "Drug: Placebo patch and pill"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "17-\u03b2 estradiol transdermal patches with cyclic progesterone",
                    "description": "17-\u03b2 estradiol transdermal patches (100 mcg 17-\u03b2 estradiol/day) with cyclic progesterone (200 mg micronized progesterone daily for 12 days every month)",
                    "armGroupLabels": [
                        "17-\u03b2 estradiol with cyclic progesterone"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Placebo patch and pill",
                    "description": "Placebo patch and pill",
                    "armGroupLabels": [
                        "Placebo"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Change in inhibition-switching performance on the Delis-Kaplan Executive Function System Color-Word Interference Test (D-KEFS CWIT) with 17-\u03b2 estradiol versus placebo",
                    "timeFrame": "Baseline to 8 weeks"
                },
                {
                    "measure": "Change in Temporal Experience of Pleasure Scale (TEPS) Consummatory Pleasure score (Range: 8-48; direction: Higher values indicate more pronounced consummatory pleasure/better outcome) with 17-\u03b2 estradiol versus placebo",
                    "timeFrame": "Baseline to 8 weeks"
                },
                {
                    "measure": "Change in delay discounting parameter k using the Monetary Choice Questionnaire with 17-\u03b2 estradiol versus placebo",
                    "timeFrame": "Baseline to 8 weeks"
                },
                {
                    "measure": "Change in Eating Disorder Inventory-3 (EDI-3) Body Dissatisfaction score (Range: 0-36; direction: Higher values indicate more pronounced body dissatisfaction/worse outcome) with 17-\u03b2 estradiol versus placebo",
                    "timeFrame": "Baseline to 12 weeks"
                },
                {
                    "measure": "Change in EDI-3 Drive for Thinness score (Range: 0-28; direction: Higher values indicate more pronounced drive for thinness/worse outcome) with 17-\u03b2 estradiol versus placebo",
                    "timeFrame": "Baseline to 12 weeks"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Change in functional magnetic resonance imaging (fMRI) activation of the dorsolateral prefrontal cortex (DLPFC) and anterior cingulate cortex (ACC) during a task switching paradigm with 17-\u03b2 estradiol versus placebo",
                    "timeFrame": "Baseline to 8 weeks"
                },
                {
                    "measure": "Change in fMRI activation of the ventromedial prefrontal cortex (VMPFC) and ventral striatum in response to reward receipt with 17-\u03b2 estradiol versus placebo",
                    "timeFrame": "Baseline to 8 weeks"
                },
                {
                    "measure": "Change in fMRI activation of the VMPFC and ventral striatum during delay discounting with 17-\u03b2 estradiol versus placebo",
                    "timeFrame": "Baseline to 8 weeks"
                },
                {
                    "measure": "Change in the Eating Disorder Examination (EDE) Dietary Restraint subscale (Range: 0-6; direction: Higher values indicate more pronounced dietary restraint/worse outcome) with 17-\u03b2 estradiol versus placebo",
                    "timeFrame": "Baseline to 12 weeks"
                },
                {
                    "measure": "Change in caloric intake by 4-day food diary with 17-\u03b2 estradiol versus placebo",
                    "timeFrame": "Baseline to 12 weeks"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion criteria:\n\n* Female\n* 14-35 years\n* Bone age \u226513.5 years (applicable only for participants \\<16 years)\n* Clinically significant eating disorder characterized by restriction and/or excessive exercise and high drive for thinness\n* Hypoestrogenemia: Oligo-amenorrhea defined as lack of menses for \u22653 months within a 6-month period of oligomenorrhea (cycle length \u22655 weeks) or absence of menses at \\>15 years if premenarchal or low estradiol levels evaluated by the study physician\n* Low or normal weight defined by a body mass index that is \\<85th percentile for 14-18 year olds and a body mass index \\<25 kg/m2 for adults\n\nExclusion criteria:\n\n* Suicidal ideation where outpatient treatment is determined unsafe by study clinician\n* Other causes of oligo-amenorrhea, unless a study clinician determines that missed menstrual periods are more likely a consequence of restrictive eating\n* Medications that contain estrogen \u00b1 progesterone within the past 3 months\n* Levonorgestrel-releasing intrauterine device if subject is unable to provide two to three weekly blood samples for estradiol of if estradiol levels are determined to be too high by study doctor\n* Neurological or psychiatric disorders that may impact neural circuitry of interest\n* Lifetime history of seizure disorder or electroconvulsive therapy\n* Pregnancy/breastfeeding\n* Gastrointestinal tract surgery\n* Contraindications to estrogen use\n* Any other significant illness or condition that the investigator determines could interfere with study participation or safety or put the subject at any unnecessary risk",
            "healthyVolunteers": false,
            "sex": "FEMALE",
            "minimumAge": "14 Years",
            "maximumAge": "35 Years",
            "stdAges": [
                "CHILD",
                "ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Madhusmita Misra, M.D., M.P.H.",
                    "role": "CONTACT",
                    "phone": "617-726-5790",
                    "email": "mmisra@mgh.harvard.edu"
                },
                {
                    "name": "Franziska Plessow, Ph.D.",
                    "role": "CONTACT",
                    "phone": "617-726-3870",
                    "email": "fplessow@mgh.harvard.edu"
                }
            ],
            "overallOfficials": [
                {
                    "name": "Madhusmita Misra, M.D., M.P.H.",
                    "affiliation": "Massachusetts General Hospital",
                    "role": "PRINCIPAL_INVESTIGATOR"
                }
            ],
            "locations": [
                {
                    "facility": "Massachusetts General Hospital",
                    "status": "RECRUITING",
                    "city": "Boston",
                    "state": "Massachusetts",
                    "zip": "02114",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Madhusmita Misra, M.D., M.P.H.",
                            "role": "CONTACT",
                            "phone": "617-726-5790",
                            "email": "mmisra@mgh.harvard.edu"
                        },
                        {
                            "name": "Kamryn Eddy, Ph.D.",
                            "role": "CONTACT",
                            "phone": "617-724-0799",
                            "email": "keddy@mgh.harvard.edu"
                        }
                    ],
                    "geoPoint": {
                        "lat": 42.35843,
                        "lon": -71.05977
                    }
                }
            ]
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000001068",
                    "term": "Feeding and Eating Disorders"
                }
            ],
            "ancestors": [
                {
                    "id": "D000001523",
                    "term": "Mental Disorders"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M4181",
                    "name": "Anorexia",
                    "relevance": "LOW"
                },
                {
                    "id": "M4182",
                    "name": "Anorexia Nervosa",
                    "relevance": "LOW"
                },
                {
                    "id": "M3909",
                    "name": "Amenorrhea",
                    "relevance": "LOW"
                },
                {
                    "id": "M4380",
                    "name": "Feeding and Eating Disorders",
                    "asFound": "Eating Disorders",
                    "relevance": "HIGH"
                },
                {
                    "id": "M4815",
                    "name": "Mental Disorders",
                    "relevance": "LOW"
                },
                {
                    "id": "M14473",
                    "name": "Psychotic Disorders",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC23",
                    "name": "Symptoms and General Pathology"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                },
                {
                    "abbrev": "BXM",
                    "name": "Behaviors and Mental Disorders"
                }
            ]
        },
        "interventionBrowseModule": {
            "meshes": [
                {
                    "id": "C000007630",
                    "term": "Estradiol 17 beta-cypionate"
                },
                {
                    "id": "C000074283",
                    "term": "Estradiol 3-benzoate"
                },
                {
                    "id": "D000004958",
                    "term": "Estradiol"
                },
                {
                    "id": "C000008958",
                    "term": "Polyestradiol phosphate"
                },
                {
                    "id": "D000011374",
                    "term": "Progesterone"
                }
            ],
            "ancestors": [
                {
                    "id": "D000004967",
                    "term": "Estrogens"
                },
                {
                    "id": "D000006728",
                    "term": "Hormones"
                },
                {
                    "id": "D000006730",
                    "term": "Hormones, Hormone Substitutes, and Hormone Antagonists"
                },
                {
                    "id": "D000045505",
                    "term": "Physiological Effects of Drugs"
                },
                {
                    "id": "D000080066",
                    "term": "Contraceptive Agents, Hormonal"
                },
                {
                    "id": "D000003270",
                    "term": "Contraceptive Agents"
                },
                {
                    "id": "D000012102",
                    "term": "Reproductive Control Agents"
                },
                {
                    "id": "D000003271",
                    "term": "Contraceptive Agents, Female"
                },
                {
                    "id": "D000011372",
                    "term": "Progestins"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M14245",
                    "name": "Progesterone",
                    "asFound": "Region",
                    "relevance": "HIGH"
                },
                {
                    "id": "M8116",
                    "name": "Estrogens",
                    "relevance": "LOW"
                },
                {
                    "id": "M266279",
                    "name": "Estradiol 17 beta-cypionate",
                    "asFound": "Segmentectomy",
                    "relevance": "HIGH"
                },
                {
                    "id": "M266280",
                    "name": "Estradiol 3-benzoate",
                    "asFound": "Segmentectomy",
                    "relevance": "HIGH"
                },
                {
                    "id": "M8108",
                    "name": "Estradiol",
                    "asFound": "Cell lymphoma",
                    "relevance": "HIGH"
                },
                {
                    "id": "M234941",
                    "name": "Polyestradiol phosphate",
                    "asFound": "Segmentectomy",
                    "relevance": "HIGH"
                },
                {
                    "id": "M9789",
                    "name": "Hormones",
                    "relevance": "LOW"
                },
                {
                    "id": "M9788",
                    "name": "Hormone Antagonists",
                    "relevance": "LOW"
                },
                {
                    "id": "M6494",
                    "name": "Contraceptive Agents",
                    "relevance": "LOW"
                },
                {
                    "id": "M2116",
                    "name": "Contraceptive Agents, Hormonal",
                    "relevance": "LOW"
                },
                {
                    "id": "M6495",
                    "name": "Contraceptive Agents, Female",
                    "relevance": "LOW"
                },
                {
                    "id": "M14244",
                    "name": "Progestins",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                },
                {
                    "abbrev": "Repr",
                    "name": "Reproductive Control Agents"
                }
            ]
        }
    },
    "hasResults": false
}